Intelligent Bio Solutions Inc SEC Filings

Intelligent Bio Solutions (INBS) reported results from its October 16 annual meeting. Stockholders approved an amendment to the 2019 Long Term Incentive Plan, increasing the share pool by 495,000 to 1,795,000 shares. They also approved, for Nasdaq Listing Rule 5635(d) purposes, the potential issuance of up to 4,147,616 shares upon warrant exercise.

Directors were elected and the appointment of UHY LLP as auditor for the fiscal year ending June 30, 2026 was ratified. Stockholders authorized a reverse stock split within a 1‑for‑2 to 1‑for‑10 range, at the Board’s discretion within 12 months, solely to help regain compliance with the Nasdaq Capital Market minimum bid price requirement. At the meeting, 4,482,941 shares voted, representing approximately 49.65% of the 9,028,712 shares outstanding as of September 11, 2025.

INTELLIGENT BIO SOLUTIONS, INC. (INBS) filed an Form 8-K reporting a material event that attaches the Form of Amended Series H-1 Warrant as an exhibit. The filing lists Exhibit 4.1 as the amended warrant form and includes an Inline XBRL cover page data file. The document is signed by Spiro Sakiris, Chief Financial Officer.

The filing notifies stakeholders that the company has documented changes to the Series H-1 warrant in a formal amended warrant agreement, but it does not disclose the economic terms, number of warrants affected, exercise price, expiration, or any related cash or equity effects.

Intelligent Bio Solutions Inc. proxy materials disclose governance and compensation program details including an Insider Trading Policy that forbids hedging transactions by directors, officers and employees and requires compliance with applicable securities laws. The company implemented a Dodd-Frank restatement recoupment (clawback) policy effective October 2, 2023 to recoup erroneously awarded incentive compensation tied to a restatement over a defined lookback period. The filing shows an equity compensation plan with 1,192,655 shares referenced and plan provisions covering stock options, SARs, restricted stock, RSUs, transfer limits, typical vesting practices and a maximum 10-year option term (five years for >10% holders). A reverse stock split amendment is being recommended by the Board for stockholder approval. The largest disclosed shareholder is Alyeska Master Fund, LP with 927,292 shares (9.99%). Executive and director compensation snippets appear (e.g., Spiro Sakiris totals and director fees) and the Plan notes that shares to be issued are not registered under the Securities Act as of the Effective Date.

Intelligent Bio Solutions Inc. preliminary proxy excerpt discloses governance and compensation policies for executives and directors. The company has an Insider Trading Policy that prohibits hedging transactions and requires compliance with securities laws. A clawback/recoupment policy applies to incentive-based compensation for executive officers in the event of a required financial restatement, covering awards received after October 2, 2023, and looking back three completed fiscal years plus certain transition periods.

The document shows director and named executive officer compensation items and totals for 2024 and 2025 (examples: Spiro Sakiris total compensation figures of $446,622 in 2024 and $363,532 in 2025; other individual director fees like $51,250, $50,625, $55,625). It outlines an equity compensation plan (2019 Plan) with current shares reserved and available: 7,154,982 securities reserved for outstanding options/warrants/rights, 100,000,000 shares authorized, and available shares under the plan of 1,192,655 (if Proposal 3 not approved) or 1,687,655 (if approved). A proposed Reverse Stock Split amendment is described as subject to shareholder approval, with the Board to fix the ratio within the approved range. A 9.99% holder is identified: Alyeska Master Fund, LP (921,825 shares).

The prospectus fragment for Intelligent Bio Solutions Inc. (INBS) discloses that the Series J Warrants have an initial exercise price of $1.90 per share, expire 5.5 years after issuance, and would convert into up to 4,046,456 shares of common stock if exercised. Exercise is conditioned on the Company receiving stockholder approval. The filing also lists key executives and directors, including CEO Harry Simeonidis and CFO Spiro Sakiris. The provided text appears partial and lacks broader financial data.

Intelligent Bio Solutions, Inc. filed an S-3 shelf registration describing ownership and disclosure exhibits. The filing lists significant holders including Alyeska Master Fund, LP with 1,758,240 shares (16.99%), CVI Investments, Inc. with 1,421,556 shares (13.74%), and Warberg WF XII LP with 1,279,120 shares (12.65%). Several other institutional and insider holdings are reported with percentages or ‘‘*’’ denoting de minimis amounts. The filing references a Form 8-A originally filed December 22, 2020, and identifies SEC registration fee of $919.16, accounting fees of $5,000.00, and a total listed as $25,919.16. The document is signed by the CEO, CFO, Chairman, and multiple directors with signature dates of August 22, 2025.